Publication | Closed Access

Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes

Hematological MalignancyErythropoietin AlphaBone Marrow FailureGranulocyte-colony Stimulating FactorAplastic AnemiaHematologyImmunologyPathologyAutoimmunityMedicineTransfusion-dependent Myelodysplastic SyndromesMyeloid Neoplasia